Aclarion, Inc. (ACON)

NASDAQ: ACON · Real-Time Price · USD
8.96
-0.18 (-1.97%)
Apr 16, 2025, 4:00 PM EDT - Market closed
-1.97%
Market Cap 5.22M
Revenue (ttm) 45,724
Net Income (ttm) -7.05M
Shares Out 582.37K
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,880
Open 9.15
Previous Close 9.14
Day's Range 8.96 - 9.38
52-Week Range 7.26 - 6,241.05
Beta 1.08
Analysts Buy
Price Target 481.00 (+5,268.3%)
Earnings Date Apr 9, 2025

About ACON

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN software application, a non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs vari... [Read more]

Sector Healthcare
IPO Date Apr 22, 2022
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ACON
Full Company Profile

Financial Performance

In 2024, Aclarion's revenue was $45,724, a decrease of -39.36% compared to the previous year's $75,404. Losses were -$7.05 million, 43.6% more than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ACON stock is "Buy." The 12-month stock price forecast is $481.0, which is an increase of 5,268.30% from the latest price.

Price Target
$481.0
(5,268.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary...

7 days ago - GlobeNewsWire

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GL...

14 days ago - GlobeNewsWire

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder eq...

16 days ago - GlobeNewsWire

Aclarion Provides Shareholder Update

BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary...

4 weeks ago - GlobeNewsWire

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary...

5 weeks ago - GlobeNewsWire

Aclarion Announces First Commercial Agreement with Scripps Health

Agreement expands access to Nociscan technology for leading spine physicians and more than 3.2M people in the greater San Diego Metro area Nociscan leverages MR Spectroscopy (MRS) and Augmented Intell...

6 weeks ago - GlobeNewsWire

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI)  NOCISCAN is an innovative decision support tool that helps physicians personalize tr...

7 weeks ago - GlobeNewsWire

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Recent Notice of Allowance is for Aclarion's 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral dis...

2 months ago - GlobeNewsWire

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan's ability to improve surgical outcomes while reducin...

2 months ago - GlobeNewsWire

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nocisca...

2 months ago - GlobeNewsWire

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients

5 months ago - GlobeNewsWire

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprieta...

5 months ago - Accesswire

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare techno...

6 months ago - GlobeNewsWire

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify M...

7 months ago - GlobeNewsWire

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON).

7 months ago - GlobeNewsWire

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions

7 months ago - GlobeNewsWire

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response

7 months ago - GlobeNewsWire

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population

7 months ago - GlobeNewsWire

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain

8 months ago - GlobeNewsWire

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data

8 months ago - GlobeNewsWire

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augm...

8 months ago - GlobeNewsWire

Aclarion Announces First Commercial Agreement in Michigan

Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor, and...

8 months ago - GlobeNewsWire

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

BROOMFIELD, CO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary aug...

8 months ago - GlobeNewsWire

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care Marke...

10 months ago - GlobeNewsWire

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First Insurance...

10 months ago - GlobeNewsWire